Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook 
Google to Move All Pixel Production Out of China by 2027 
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Shein Targets $26B-$27B Valuation for Hong Kong IPO 
Add as a preferred source on Google
Boryung Pharmaceutical has added Eli Lily's Gemzar among the anti-cancer drugs that it has rights to distribute in South Korea.
Boryung also has distribution rights to such anti-cancer drugs as Oxalitin (oxaliplatin) and Genexol (paclitaxel).
Boryung CEO Ahn Jae-hyun promised to continue growing its anti-cancer portfolio as the company's focal point.
Gemzar (gemcitabine), a nucleoside metabolic inhibitor, is mainly a pancreatic cancer treatment drug.
Combined with other drugs, Gemzar is used for the treatment of metastatic breast cancer, advanced ovarian cancer, and non-small cell lung cancer.
Gemzar posted 14.2 billion won in revenue in South Korea last year.
